Abbott Laboratories which can be found using ticker (ABT) have now 21 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $143.00 and $105.23 calculating the mean target share price we have $124.04. (at the time of writing). Now with the previous closing price of $114.40 and the analysts are correct then we can expect a percentage increase in value of 8.4%. Also worth taking note is the 50 day moving average now sits at $107.55 and the 200 day moving average is $109.01. The market cap for the company is 196.78B. Currently the stock stands at: $113.10 USD
The potential market cap would be $213,364,723,752 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 35.68, revenue per share of $23.40 and a 6.25% return on assets.
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
